var data={"title":"Corticorelin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Corticorelin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/44080?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=corticorelin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Corticorelin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3281687\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Acthrel</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3281690\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3284295\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cushing syndrome, differential diagnosis:</b> IV:  1 mcg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Interpretation of results:</b> <b>Note:</b> Basal and peak responses differ depending on AM or PM administration; therefore, any repeat evaluations on the same patient are recommended to be done at the same time of day as the initial testing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Increased plasma ACTH and cortisol concentrations following administration:</i> Patients with Cushing disease will exhibit high basal plasma ACTH plus high basal plasma cortisol (20 to 40 mcg/dL). Corticorelin administration will result in increased plasma ACTH and cortisol concentrations. This response pattern indicates an impairment of the negative feedback of cortisol on the pituitary. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Little or no response of plasma ACTH and cortisol concentrations following administration:</i> Patients with ectopic production of ACTH will exhibit high basal plasma ACTH (may be very high) plus high basal plasma cortisol (20 to 40 mcg/dL). Corticorelin administration will result in little or no response of plasma ACTH and cortisol concentrations. Clinicians should note that there have been rare instances of patients with ectopic sources of ACTH that have responded to the corticorelin test.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45092601\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Cushing syndrome, differential diagnosis:</b> Children and Adolescents: Refer to adult dosing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15795903\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15795904\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3284298\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as trifluoroacetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acthrel: 100 mcg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3281689\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3284296\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Prior to administration, obtain venous blood samples 15 minutes before and immediately prior to injection to determine baseline ACTH and cortisol concentrations. Administer over 30 to 60 seconds. Concurrent heparin (even to maintain IV patency) is not recommended. Obtain venous blood samples at 15, 30, and 60 minutes after administration to evaluate ACTH and cortisol response. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3281691\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Cushing syndrome, differential diagnosis:</b> Used as a diagnostic aid to differentiate between pituitary and ectopic production of ACTH in patients with ACTH-dependent disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3281685\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acthrel may be confused with Acthar</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Corticorelin may be confused with corticotropin, cosyntropin, or Cortrosyn</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3284278\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Frequency not always defined. Incidence of adverse effects is dependent upon dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Decreased blood pressure (7%), asystole, flushing (face, neck, and upper chest), palpitations (Corticorelin 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Tonic-clonic seizures (1%), dizziness, (Corticorelin 2004), metallic taste (Corticorelin 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Vomiting (Corticorelin 2004), xerostomia (Corticorelin 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea (urge to inspire)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Angioedema, chest tightness, hypotension (severe), increased heart rate, loss of consciousness, tachycardia (severe), wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3284274\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ovine corticorelin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3284275\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular effects: High doses (&gt;1 mcg/kg or &gt;100 mcg) have been associated with asystole, hypotension, transient tachycardia, and syncope; cardiovascular effects occur 2 to 3 minutes after injection and may last 30 to 60 minutes. Do not exceed the recommended dose or rate of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Use may result in hypersensitivity reactions, including urticaria, flushing of the face, neck and upper chest; dyspnea, wheezing, urticaria and angioedema; high doses (&gt;3 mcg/kg) are associated with more prolonged flushing (up to 4 hours), dyspnea, and chest tightness. Discontinue use if hypersensitivity occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; False-negative responses: May occur in 5% to 10% of patients with Cushing disease, which may lead to an incorrect diagnosis of ectopic production of ACTH. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299094\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3284285\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8866&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids: May diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.<b> Exceptions: </b>Beclomethasone (Nasal); Budesonide (Nasal); Ciclesonide (Nasal); Desonide; Dexamethasone (Ophthalmic); Difluprednate; Flunisolide (Nasal); Fluocinolone (Ophthalmic); Fluticasone (Nasal); Hydrocortisone (Ophthalmic); Loteprednol; Mometasone (Nasal); PrednisoLONE (Ophthalmic); Triamcinolone (Nasal); Triamcinolone (Ophthalmic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: May enhance the adverse/toxic effect of Corticorelin. Significant hypotension and bradycardia have been previously attributed to this combination.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3284271\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3284272\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20613969\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if corticorelin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering corticorelin to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45093671\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ACTH and cortisol concentrations at 15 minutes prior to administration, at administration, and at 15, 30, and 60 minutes postinjection; blood pressure, heart rate, signs and symptoms of hypersensitivity reaction. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3284289\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">High basal plasma ACTH and cortisol (20 to 40 mcg/dL) resulting in <b>increased</b> plasma ACTH and cortisol after administration of test indicates <b>ACTH-dependent disease of pituitary origin (eg, Cushing disease).</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">High basal plasma ACTH (may be very high) and cortisol (20 to 40 mcg/dL) resulting in <b>little to no change</b> in plasma ACTH and cortisol after administration of test indicates <b>ACTH-dependent syndrome of ectopic origin.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3284287\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Corticorelin ovine, a peptide of ovine corticotropin-releasing hormone (oCRH) and an analogue of human CRH (hCRH), stimulates adrenocorticotropic hormone (ACTH) release from the anterior pituitary. ACTH stimulates the adrenal cortex to produce cortisol. Depending on the plasma ACTH and cortisol response following the corticorelin stimulation test, the results aid the clinician in the differentiation between the source of ACTH-dependent hypercortisolism (pituitary vs ectopic).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3284290\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plasma ACTH concentration: Increases 2 minutes after injection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plasma cortisol concentration: Increases within 10 minutes after injection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Response to injection is biphasic with a second lower peak 2 to 3 hours postinjection; basal and peak response levels vary depending on AM or PM administration. In general, baseline ACTH and cortisol concentrations are higher in the AM.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Plasma ACTH concentration: Initial peak: 15 to 60 minutes after injection</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Plasma cortisol concentration: Initial peak at 30 to 120 minutes after injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: IV: Plasma ACTH and cortisol concentrations remain elevated for up to 2 hours after injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 6.2 &plusmn; 0.5 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Does not appear to be bound by circulating plasma protein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: t<sub>1/2</sub>: Exhibits biexponential decay; Fast component: 11.6 &plusmn; 1.5 minutes; slow component: 73 &plusmn; 8 minutes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322950\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Acthrel Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (1): $1,001.64</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12992804\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>CRH (AT, DE, NL);</li>\n      <li>CRH-Ferring (KR);</li>\n      <li>Stimu-ACTH (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Acthrel (corticorelin) [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corticorelin: ACTH RF, corticoliberin, corticotrophin-releasing hormone, corticotropin-releasing factor, human corticotropin-releasing hormone, ovine corticotrophin-releasing factor, Xerecept. <i>Drugs R D</i>. 2004;5(4):218-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/corticorelin-drug-information/abstract-text/15230628/pubmed\" target=\"_blank\" id=\"15230628\">15230628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newell-Price J, Bertagna X, Grossman AB, et al, &ldquo;Cushing&rsquo;s Syndrome,&rdquo; <i>Lancet</i>, 2006, 367(9522):1605-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/corticorelin-drug-information/abstract-text/16698415/pubmed\" target=\"_blank\" id=\"16698415\">16698415</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nieman LK, Oldfield EH, Wesley R, et al, &ldquo;A Simplified Morning Ovine Corticotropin-Releasing Hormone Stimulation Test for the Differential Diagnosis of Adrenocorticotropin-Dependent Cushing&rsquo;s Syndrome,&rdquo; <i>J Clin Endocrinol Metab</i>, 1993, 77(5):1308-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/corticorelin-drug-information/abstract-text/8077325/pubmed\" target=\"_blank\" id=\"8077325\">8077325</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8866 Version 78.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F3281687\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F3281690\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F3284295\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F45092601\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15795903\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15795904\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F3284298\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F3281689\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3284296\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F3281691\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3281685\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3284278\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3284274\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3284275\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299094\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F3284285\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F3284271\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3284272\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20613969\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45093671\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F3284289\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3284287\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F3284290\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322950\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12992804\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8866|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=corticorelin-patient-drug-information\" class=\"drug drug_patient\">Corticorelin: Patient drug information</a></li></ul></div></div>","javascript":null}